Understanding the pathology of schizophrenia: Recent advances from the study of the molecular architecture of postmortem CNS tissue

Postgraduate Medical Journal

Volumn 78, Issue 917, 2002, Pages 142-148

  Dean, Brian ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; SEROTONIN; WNT PROTEIN;

BRAIN TISSUE; CADAVER; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HUMAN; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; PATHOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TRANSCRIPTION REGULATION;

BRAIN; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA;

EID: 0036122714     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.78.917.142     Document Type: Review

References (60)

1. Meeting report; "Molecular neurobiological mechanisms in schizophrenia: Seeking a synthesis"
2. Biochemical studies in schizophrenia
3. Schizophrenia: Elevated mRNA for dopamine D2(longer) receptors in frontal cortex
4. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain
5. Changes in serotonin2A and GABA(A) receptors in schizophrenia: Studies on the human dorsolateral prefrontal cortex
6. The evolution of the serotonin-dopamine antagonist concept
7. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia
8. No change in the density of the serotonin 1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia
9. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?
10. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment
11. 3H]muscimol binding, in Brodmann's area 9 from subjects with bipolar disorder
12. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia
13. Linkage and associated studies of schizophrenia
14. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia
15. 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia
16. Cholinergic aspects of schizophrenia
17. Acetylcholine
18. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia
19. Schizophrenia and smoking: An epidemiological survey in a state hospital
20. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome
21. Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication
22. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia
23. Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation
24. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: No change in m1 mRNA in schizophrenia
25. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia
26. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine
27. The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels
28. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia
29. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus
30. Decreased hippocampal (CA3) NMDA receptors in schizophrenia
31. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
32. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
33. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients
34. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics
35. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics
36. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: Focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression
37. GABA transporter-1 mRNA in prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons
38. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics
39. 3H]CP-55940 binding in the human central nervous system: Regional specific changes in the density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
40. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia
41. Protein phosphorylation and the regulation of synaptic membrane traffic
42. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia
43. Normal cellular levels of synaptophysin mRNA expression in the prefrontal cortex of subjects with schizophrenia
44. SNAP-25 deficit and hippocampal connectivity in schizophrenia
45. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains
46. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia
47. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness
48. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex
49. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients
50. Signal transduction by the Wnt family of ligands
51. Increased expression of Wnt-1 in schizophrenic brains
52. Low GSK-3beta, immunoreactivity in postmortem frontal cortex of schizophrenic patients
53. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia
54. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: Implications for the pathophysiology of psychiatric disorders
55. A decrease of reelin expression as a putative vulnerability factor in schizophrenia
56. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia
57. Genetics and schizophrenia
58. Alzheimer's disease: Genes, proteins, and therapy
59. The Worster-Drought syndrome and other syndromes of dementia with spastic paraparesis: The paradox of molecular pathology
60. The Wnt/Ca2+ pathway: A new vertebrate Wnt signaling pathway takes shape